Fc-Linker Drug Conjugate Preparation for Higher Long-Acting Yield
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Physiologically active polypeptides are unstable, easily degraded by proteases, and have short serum half-lives, necessitating frequent injections that cause patient discomfort and increase treatment costs, while existing methods to enhance stability and duration, such as PEGylation, suffer from yield decreases and immune responses.
Innovation Solution
A novel intermediate compound with a structure of Formula 1, comprising an immunoglobulin Fc region linked to a linker, is used to prepare a long-acting drug conjugate by linking to a physiologically active polypeptide, omitting ultrafiltration/diafiltration and hydrophobic interaction chromatography steps.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If PEGylation is used to extend in vivo duration, then stability and duration of action are improved, but titer significantly decreases and yield decreases due to low reactivity
Solution Approach 1:
The patent introduces a two-step conjugation process using an intermediate compound. First, the immunoglobulin Fc region is conjugated to a linker compound (containing reactive groups like maleimide or aldehyde). Second, the physiologically active polypeptide is conjugated to this intermediate. This intermediary approach protects the polypeptide from direct exposure to harsh conjugation conditions and maintains higher reactivity and yield while achieving the desired long-acting effect.
2Duration of action of moving object
If PEG molecular weight is increased to extend duration, then in vivo duration is improved, but titer significantly decreases
Solution Approach 1:
The patent optimizes the parameters of the linker compound, specifically using PEG with molecular weights in the range of 1,000-10,000 Da (preferably 2,000-5,000 Da), rather than higher molecular weights. This parameter optimization balances the extension of in vivo duration with maintenance of adequate titer levels, resolving the contradiction between duration and quantity.
3Quantity of substance
If frequent administration is implemented to maintain blood concentration, then blood concentration is maintained, but patient discomfort increases and treatment costs increase
Solution Approach 1:
The patent creates a long-acting drug conjugate in advance by chemically linking the physiologically active polypeptide to an immunoglobulin Fc region via a linker. This preliminary conjugation action extends the half-life of the drug, allowing maintenance of therapeutic blood concentration over extended periods (weeks to months) rather than requiring frequent injections, thereby reducing patient discomfort and treatment costs.
4Quantity of substance
If long-acting formulation is developed to maintain titer, then blood concentration is maintained, but immune responses may be induced
Solution Approach 1:
The patent optimizes the linker compound parameters, specifically using PEG with controlled molecular weight (1,000-10,000 Da) and specific structural features (Formula 2 or 3 configurations), to achieve long-acting effect while minimizing immunogenicity. The optimized parameters balance extended duration with reduced immune response.
Solution Approach 2:
The patent introduces structural heterogeneity through the linker design, where different regions of the conjugate have different properties: the PEG portion provides hydrophilicity and extended circulation, while the immunoglobulin Fc region provides long half-life through FcRn recycling, and the polypeptide provides therapeutic activity. This local quality differentiation allows each component to contribute its optimal function while minimizing overall immunogenicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method increases the yield and productivity of long-acting drug conjugates, maintaining high blood concentration with reduced immune response and frequency of administration.
Implementation Method 1
linking a linker compound of Formula 2 or 3 to an immunoglobulin Fc region to prepare a conjugate
Implementation Method 2
linking the linker compound, to which the immunoglobulin Fc region has been linked, to a physiologically active polypeptide
Data Source
AI summary
Provided is a novel method for preparing a long-acting drug conjugate and a long-acting drug conjugate prepared using the method.